Colesevelam for Hyperlipidemia and Microscopic Colitis: Evidence‑Based Recommendations

Indications and Efficacy

Add‑on lipid therapy: 2018 cardiovascular guidelines endorse bile‑acid sequestrants as add‑on agents when LDL‑C remains elevated despite statin therapy. [2][3]
Prevalence of bile‑acid diarrhea: 41 % of patients with collagenous colitis and 29 % of those with lymphocytic colitis have bile‑acid diarrhea. 4
Efficacy after cholestyramine failure: Approximately 50 % of patients who do not respond to cholestyramine achieve symptom relief with colesevelam, making it an effective alternative. [4][5]

Superior tolerability: Colesevelam’s adverse‑event profile is comparable to placebo, whereas cholestyramine is linked to significant gastrointestinal distress. [2][3]

Avoid in extensive ileal resection/short‑bowel syndrome: In patients with >100 cm ileal resection or short‑bowel syndrome, bile‑acid sequestrants can exacerbate steatorrhea and fat‑soluble vitamin deficiencies. 5
Potential response despite cholestyramine failure: 44 % of patients with confirmed bile‑acid diarrhea who fail cholestyramine may still respond to colesevelam. [4][5]

Non‑response protocol: If no clinical improvement is observed after 8 weeks at the maximum dose of 3.75 g/day, clinicians should consider adding a statin for lipid control or investigating alternative etiologies of diarrhea. 5